

In the Claims

The following amendments are made with respect to the claims in the International application PCT/GB2004/004446.

This listing of claims will replace all prior versions and listings of claims in this application.

1 (currently amended). ~~Use of a non-opioid analgesic for the manufacture of a medicament for A method for~~ the treatment of intermittent or episodic pain experienced by a patient undergoing chronic pain treatment with an opioid analgesic wherein said method comprises administering to the patient a non-opioid analgesic.

2 (currently amended). [[Use]] The method according to claim 1, wherein the pain is chronic benign pain.

3 (currently amended). [[Use]] The method according to claim 2, wherein the pain is related to a musculoskeletal, visceral or headache condition.

4 (currently amended). [[Use]] The method according to claim 3, wherein the condition is osteoarthritis, rheumatoid arthritis, chronic back pain, chronic pancreatitis or chronic migraine.

5 (currently amended). [[Use]] The method according to claim 1, wherein the pain is breakthrough pain in cancer.

6 (currently amended). [[Use]] The method according to claim 5, wherein the cancer breakthrough pain is primarily neuropathic.

7 (currently amended). ~~Use according to any preceding claim~~ The method according to claim 1, wherein the non-opioid analgesic is a potentiation of the opioid analgesic.

8 (currently amended). ~~Use according to any preceding claim~~ The method according to claim 1, wherein the non-opioid analgesic is selected from antagonists of NMDA, CCK, substance P or Neurokinin, compounds that cause uptake blockade, agonists of alpha₂ or beta₂ adrenoceptors, and COX inhibitors.

9 (currently amended). ~~Use according to any preceding claim~~ The method according to claim 1, wherein the non-opioid analgesic is selected from clenbuterol, proglumide, devazepide, ifenprodil, nefopam, tramadol, duloxetine and venlafaxine.

10 (currently amended). ~~Use according to any preceding claim, wherein the medicament is for administration~~ The method, according to claim 1, where the administration is done via a route that avoids first-pass metabolism.

11 (currently amended). [[Use]] The method according to claim 10, wherein the route is intranasal.

12 (currently amended). [[Use]] The method according to claim 10, wherein the route is sublingual.

13 (currently amended). [[Use]] The method according to claim 10, wherein the route is pulmonary.

14 (original). A product comprising an opioid analgesic and a non-opioid analgesic, as a combined preparation for simultaneous, separate or sequential use in the treatment of chronic pain including intermittent or episodic pain.

15 (currently amended). [[A]] The product according to claim 14, wherein the non-opioid analgesic is ~~as defined in any of claims 7 to 9~~ a potentiation of the opioid analgesic.

16 (new). The product according to claim 14, wherein the non-opioid analgesic is selected from antagonists of NMDA, CCK, substance P or Neurokinin, compounds that cause uptake blockade, agonists of alpha₂ or beta₂ adrenoceptors, and COX inhibitors.

17 (new). The product according to claim 14, wherein the non-opioid analgesic is selected from clenbuterol, proglumide, devazepide, ifenprodil, nefopam, tramadol, duloxetine and venlafaxine.